Kaliaperumal Kumaravel, Salendra Limbadri, Liu Yonghong, Ju Zhiran, Sahu Sunil Kumar, Elumalai Sanniyasi, Subramanian Kumaran, M Alotaibi Nahaa, Alshammari Nawaf, Saeed Mohd, Karunakaran Rohini
Unit of Biomaterials Division, Department of Orthodontics, Saveetha Dental College and Hospitals, SIMATS, Saveetha University, Chennai, India.
New Use Agriculture and Natural Plant Products Program, Department of Plant Biology, Rutgers University, New Brunswick, NJ, United States.
Front Microbiol. 2023 Oct 2;14:1216928. doi: 10.3389/fmicb.2023.1216928. eCollection 2023.
Fungus-derived secondary metabolites are fascinating with biomedical potential and chemical diversity. Mining endophytic fungi for drug candidates is an ongoing process in the field of drug discovery and medicinal chemistry. Endophytic fungal symbionts from terrestrial plants, marine flora, and fauna tend to produce interesting types of secondary metabolites with biomedical importance of anticancer, antiviral, and anti-tuberculosis properties.
An organic ethyl acetate extract of sponge-derived endophytic fungi from yielded seven different secondary metabolites which are purified through HPLC. The isolated compounds are of averufin (1), aspergilol-A (2), sulochrin (3), monomethyl sulochrin (4), methyl emodin (5), citreorosein (6), and diorcinol (7). All the seven isolated compounds were characterized by high-resolution NMR spectral studies. All isolated compounds', such as anticancer, antimicrobial, anti-tuberculosis, and antiviral, were subjected to bioactivity screening.
Out of seven tested compounds, compound (1) exhibits strong anticancer activity toward myeloid leukemia. HL60 cell lines have an IC concentration of 1.00μm, which is nearly significant to that of the standard anticancer drug taxol. A virtual computational molecular docking approach of averufin with HL60 antigens revealed that averufin binds strongly with the protein target alpha, beta-tubulin (1JFF), with a -10.98 binding score. Consecutive OSIRIS and Lipinski ADME pharmacokinetic validation of averufin with HL60 antigens revealed that averufin has good pharmacokinetic properties such as drug score, solubility, and mutagenic nature. Furthermore, aspergilol-A (2) is the first report on the fungal strain.
We concluded that averufin (1) isolated from can be taken for further preliminary clinical trials like animal model studies and pharmacodynamic studies. A future prospect of anticancer screening of averufin can be validated through the present experimental findings.
真菌衍生的次生代谢产物具有生物医学潜力和化学多样性,令人着迷。在药物发现和药物化学领域,从内生真菌中挖掘候选药物是一个持续的过程。来自陆地植物、海洋植物群和动物群的内生真菌共生体往往会产生具有抗癌、抗病毒和抗结核特性等生物医学重要性的有趣类型的次生代谢产物。
从海绵衍生的内生真菌中提取的有机乙酸乙酯提取物产生了七种不同的次生代谢产物,通过高效液相色谱法进行纯化。分离出的化合物为阿弗菌素(1)、曲霉酚 - A(2)、苏罗克菌素(3)、单甲基苏罗克菌素(4)、甲基大黄素(5)、柠檬玫瑰红素(6)和二羟基萘酚(7)。所有七种分离出的化合物都通过高分辨率核磁共振光谱研究进行了表征。对所有分离出的化合物进行了抗癌、抗菌、抗结核和抗病毒等生物活性筛选。
在七种测试化合物中,化合物(1)对髓系白血病表现出强烈的抗癌活性。HL60细胞系的IC浓度为1.00μm,与标准抗癌药物紫杉醇的浓度几乎相当。阿弗菌素与HL60抗原的虚拟计算分子对接方法表明,阿弗菌素与蛋白质靶点α,β - 微管蛋白(1JFF)强烈结合,结合分数为 - 10.98。对阿弗菌素与HL60抗原进行连续的OSIRIS和Lipinski药物代谢动力学验证表明,阿弗菌素具有良好的药物代谢动力学特性,如药物分数、溶解度和致突变性。此外,曲霉酚 - A(2)是该真菌菌株的首次报道。
我们得出结论,从[具体来源未提及]分离出的阿弗菌素(1)可用于进一步的初步临床试验,如动物模型研究和药效学研究。阿弗菌素抗癌筛选的未来前景可通过本实验结果得到验证。